Phase II trial of trimetrexate in untreated advanced gastric carcinoma - A Southwest Oncology Group study

Alexander Hantel, Catherine M. Tangen, John S. Macdonald, Stephen P. Richman, Reginald P. Pugh, Theodore Pollock

Research output: Contribution to journalArticle

5 Scopus citations


Twenty-three evaluable patients with advanced gastric adenocarcinoma were treated with trimetrexate at doses of 8-12 mg/m2 intravenously daily for five days, with cycles repeated every 21 days. One complete response was seen for an overall response rate of 4% (95% confidence interval 0-22%). Hematologie toxicities of grade ≥ 3 were seen in 10/23 patients, and overall any grade 3 or greater toxicity was seen in 14/ 23 patients. Trimetrexate has minimal activity against gastric adenocarcinoma in this study, and no further investigation of this agent at this dose and schedule is recommended in this disease.

Original languageEnglish (US)
Pages (from-to)155-157
Number of pages3
JournalInvestigational New Drugs
Issue number2
StatePublished - Jun 1 1994



  • gastric adenocarcinoma
  • trimetrexate

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this